PRO DEX Inc income statement
In fiscal 2026, PRO DEX Inc reported revenue of $77.5m, up 16.5% on the year before, operating income of $13.0m (a 16.8% margin) and net income of $13.7m, or $4.12 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2011Jun 2011 | 2012Jun 2012 | 2013Jun 2013 | 2014Jun 2014 | 2015Jun 2015 | 2016Jun 2016 | 2017Jun 2017 | 2018Jun 2018 | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Jun 2022 | 2023Jun 2023 | 2024Jun 2024 | 2025Jun 2025 | 2026Jun 2026 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24 | 17 | 12 | 11 | 13 | 20 | 22 | 22 | 27 | 35 | 38 | 42 | 46 | 54 | 67 | 78 | 80 |
| Cost of revenue | 14 | 12 | 9 | 8 | 10 | 14 | 15 | 15 | 17 | 22 | 24 | 29 | 33 | 39 | 47 | 53 | 54 |
| Gross profit | 10 | 5 | 4 | 3 | 4 | 5 | 7 | 8 | 10 | 13 | 14 | 13 | 13 | 15 | 20 | 24 | 26 |
| Research and development | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 4 | 3 | 3 | 3 | 4 | 3 | 4 |
| Selling, general and administrative | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 5 | 8 | 9 |
| General and administrative | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 4 | 5 | 4 | 4 | — | — | — |
| Operating income | 3 | −1 | −2 | −1 | −1 | 1 | 3 | 2 | 5 | 7 | 5 | 5 | 6 | 7 | 11 | 13 | 13 |
| Interest expense | −0 | −0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Income before tax | 3 | −1 | −2 | −1 | −0 | 1 | 3 | 3 | 5 | 8 | 8 | 6 | 9 | 3 | 12 | 18 | 15 |
| Income tax | 1 | −0 | −0 | −0 | −0 | 0 | −2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 3 | 4 | 3 |
| Net income | 3 | −1 | −2 | −0 | −0 | 1 | 5 | 2 | 4 | 6 | 6 | 5 | 7 | 2 | 9 | 14 | 12 |
| Diluted EPS | $0.80 | −$0.27 | −$0.54 | −$0.14 | −$0.09 | $0.20 | $1.25 | $0.37 | $0.97 | $1.50 | $1.57 | $1.21 | $1.95 | $0.60 | $2.67 | $4.12 | $3.63 |
| Diluted shares (average) | 3m | 3m | 3m | 3m | 4m | 4m | 4m | 4m | 4m | 4m | 4m | 4m | 4m | 4m | 3m | 3m | 3m |
| EBITDA | 4 | −1 | −1 | −0 | −0 | 1 | 3 | 3 | 5 | 8 | 5 | 6 | 7 | 8 | 12 | 14 | 15 |
| Quarter | 2025 Q2Dec 2024 | 2025 Q3Mar 2025 | 2025 Q4Jun 2025 | 2026 Q1Sept 2025 | 2026 Q2Dec 2025 | 2026 Q3Mar 2026 | 2026 Q4Jun 2026 | 2027 Q1Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 17 | 17 | 17 | 19 | 19 | 20 | 20 | 21 |
| Cost of revenue | 12 | 12 | 14 | 13 | 13 | 14 | 13 | 14 |
| Gross profit | 5 | 6 | 3 | 5 | 6 | 6 | 7 | 7 |
| Research and development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Selling, general and administrative | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 2 |
| Operating income | 3 | 4 | 1 | 3 | 3 | 3 | 4 | 4 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 3 | 5 | 2 | 6 | 3 | 5 | 4 | 3 |
| Income tax | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 0 |
| Net income | 2 | 3 | 1 | 5 | 2 | 4 | 3 | 3 |
| Diluted EPS | $0.61 | $0.98 | $0.36 | $1.40 | $0.66 | $1.20 | $0.85 | $0.92 |
| EBITDA | 3 | 4 | 2 | 3 | 4 | 3 | 4 | 4 |
Compare with peers
- Tela Bio, Inc. income statement
- Sight Sciences, Inc. income statement
- Avita Medical, Inc. income statement
- Electromed, Inc. income statement
- Pulmonx Corp income statement
Head to head: PDEX vs TELAPDEX vs SGHTPDEX vs RCELELMD vs PDEX
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies